Company
Pheast Therapeutics
Also known as Pheast Therapeutics, Inc
- Business model
- B2B
- Legal name
- Pheast Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
At Pheast Therapeutics, we are developing new innate immune checkpoint inhibitors, including anti-CD24, to unleash the power of macrophages on aggressive cancers.
Funding snapshot
- Total raised
- $99.8MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $24.6M2025-10-07
Funding rounds
- Round, 2025
- $24.6M2025-10-07, SEC form D sold, 7 investors
- Round, 2022
- $75.2M2022-01-31, SEC form D sold, 7 investors
Loading relationship preview